

RESEARCH ARTICLE

Open Access



Synergistic interaction of hTGF- β_3 with hBMP-6 promotes articular cartilage formation in chitosan scaffolds with hADSCs: implications for regenerative medicine

Yijiang Huang¹, Daniel Seitz², Yan Chevalier¹, Peter E. Müller¹, Volkmar Jansson¹ and Roland M. Klar^{1*}

Abstract

Background: Human TGF- β_3 has been used in many studies to induce genes coding for typical cartilage matrix components and accelerate chondrogenic differentiation, making it the standard constituent in most cultivation media used for the assessment of chondrogenesis associated with various stem cell types on carrier matrices. However, in vivo data suggests that TGF- β_3 and its other isoforms also induce endochondral and intramembranous osteogenesis in non-primate species to other mammals. Based on previously demonstrated improved articular cartilage induction by using hTGF- β_3 and hBMP-6 together on hADSC cultures and the interaction of TGF- β with matrix in vivo, the present study investigates the interaction of a chitosan scaffold as polyanionic polysaccharide with both growth factors. The study analyzes the difference between chondrogenic differentiation that leads to stable hyaline cartilage and the endochondral ossification route that ends in hypertrophy by extending the usual panel of investigated gene expression and stringent employment of quantitative PCR.

Results: By assessing the viability, proliferation, matrix formation and gene expression patterns it is shown that hTGF- β_3 + hBMP-6 promotes improved hyaline articular cartilage formation in a chitosan scaffold in which *ACAN* with *Col2A1* and not *Col1A1* nor *Col10A1* where highly expressed both at a transcriptional and translational level. Inversely, hTGF- β_3 alone tended towards endochondral bone formation showing according protein and gene expression patterns.

Conclusion: These findings demonstrate that clinical therapies should consider using hTGF- β_3 + hBMP-6 in articular cartilage regeneration therapies as the synergistic interaction of these morphogens seems to ensure and maintain proper hyaline articular cartilage matrix formation counteracting degeneration to fibrous tissue or ossification. These effects are produced by interaction of the growth factors with the polysaccharide matrix.

Keywords: Chitosan, Promotion, Adipose-derived stem cell, Articular Chondrogenesis, Bone formation, hTGF- β_3 , hBMP-6, Synergism, Validation

* Correspondence: roland.klar@med.uni-muenchen.de

¹Department of Orthopaedics, Physical Medicine and Rehabilitation, University Hospital of Munich, 81377 Munich, Germany
Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Healthy articular cartilage lacks self-repairing capacities due to its avascular structure. This makes self-regeneration and self-healing impossible, unlike bone, which can lead to functional limitations and pain eventually associated to osteoarthritis [1–4]. Compared to other therapies, autologous chondrocyte implantation has emerged as a promising technique in orthopedic surgery to treat cartilage defects [5–9]. However, autologous chondrocyte implantation suffers from several limitations. Often a cartilage graft is harvested from an articular joint, which can cause distinct donor site morbidity, limiting the supply of autologous chondrocytes [10–12]. Stem cell-based therapies are an alternative to overcome the poor self-repair capacity of cartilage, where, under the principle of tissue engineering, an insoluble substratum is combined with soluble signals [13–15]. For cartilage regeneration, chondrocytes or stem cells are often combined with a biomimetic biomaterial that supports the formation of neo-cartilage tissue with the typical characteristics of hyaline articular cartilage [16].

Extracellular matrix-like scaffolds can provide a structural template for cartilage development and also serve as a substrate that helps to facilitate cell attachment, proliferation, differentiation to the desired phenotype and integration into the adjacent cartilage [17–19]. The type of biomaterial and the architecture on cellular scale are key elements in the development of new materials for causing targeted stem cell differentiation into specific tissue types [20]. With a wide range of natural and synthetic polymers available, selecting the appropriate biomaterial is crucial [21, 22], as the material needs to both provide the necessary clues for cell development and differentiation and possess excellent biocompatibility for safe implantation. The polysaccharide chitosan, a component of crustacean and insect exoskeletons [23–25], is a copolymer of glucosamine and N-acetyl-glucosamine, obtained by the deacetylation of chitin. It is the most widely used biopolymer in various biomedical applications because of its potential to stimulate hemostasis and accelerate the regeneration of damaged or lost tissues in the process of wound healing [26, 27]. It has a hydrophilic surface that enhances cell adhesion, proliferation and differentiation, efficiently attracting fluids and cells to the defect site [28]. Chitosan has been shown to mimic native matrix components in their interaction with developing chondrocytes and possess excellent biocompatibility [29], biodegradability and physicochemical properties mimicking native chondrogenic matrix, making it suitable for cartilage tissue engineering [27, 30]. When combined with predisposed stem cells and morphogens it could become a viable alternative to other cartilage tissue engineering candidates. However, as our

previous research has shown, chitosan on its own has only very limited articular cartilage forming capabilities which has to a great extent limited its use clinically [31].

In the chondrogenic differentiation process of mesenchymal stem or stromal cells (MSCs), members of the transforming growth factor β (TGF- β) supergene family play a crucial role [32–34]. Building on previous results for the interaction of TGF- β with chitosan, we aim to investigate whether combinations with other TGF- β superfamily members, specifically hBMP-6, increases articular cartilage formation potential as compared to the effect of TGF- β_3 used alone or in combination with IGF-I. TGF- β_3 has been described in various studies to promote cartilage repair and accelerate cartilage differentiation, upregulating the expression of genes typical for the formation of cartilage in hADSCs [33, 35]. The same genes, however, are activated in growth plate chondrocytes when endochondral ossification ensues. A previous study documented that TGF- β_1 and TGF- β_3 have a similar effect on cell proliferation, gene expression and articular cartilage biosynthetic activity in ADSCs cultured in alginate beads [36]. Cals et al. [37] reported that no significant differences in total collagen and GAG formation could be observed among MSCs cultured in medium containing the three TGF- β isoforms, respectively. Some other previous studies found that TGF- β_3 was more efficient and potent than TGF- β_1 in enhancing hADSCs and MSCs chondrogenic differentiation [38]. Other studies again have also shown that TGF- β_3 is very beneficial for cartilage as it stimulates chondrocytes in vitro by inducing the elevation of proteoglycans and the production of collagen type II [32, 34, 39]. However, studies in a primate model have consistently shown that hTGF- β_3 induces endochondral ossification rather than true articular cartilage formation in vivo, with recent research suggesting that the addition of human bone morphogenetic protein 6 (hBMP-6) promotes formation of hyaline, articular-like cartilage formation of both MSCs and hADSCs [31, 40–43].

Cellular chondrogenic differentiation pathways are influenced by BMPs via specific type I and type II BMP-receptors, activating Smads pathways [44]. BMP-6 is mainly expressed in cartilaginous tissue, in which mesenchymal cell differentiation into chondrocytes is stimulated, promoting the synthesis of chondrocytes and articular cartilage-specific glycoproteins [45]. At the same time, BMP-6 is also a known factor involved in the induction of bone formation [46], indicating a multifunctionality in the regulation of bone and cartilage cell development similar to most BMPs and other growth factors of the TGF- β superfamily. Though diverse groups have shown that BMP-6 can stimulate chondrocyte and cartilage formation [47, 48], to date results remain unspecific as to whether hyaline articular or

endochondral ossification type cartilage is formed, making interpretations or validations problematic.

As various studies have assessed the biocompatibility and tissue engineering capabilities of pure and porous chitosan scaffolds with ADSCs, the primary aim of the present study was determining if the *in vitro* cartilage formation potential can be directed towards lasting, hyaline articular tissue when using a chondrogenic medium supplemented with hTGF- β_3 and hBMP-6 as opposed to the standard chondrogenic medium normally containing only hTGF- β_3 . Subsequently, the study also sought to validate our previous research [31] that the matrix formation was articular and that hTGF- β_3 alone causes endochondral bone formation and does not support articular chondrogenesis. Answering these questions can not only lead to improved *in vitro* models for consistent hyaline cartilage formation with biomimetic biomaterials, but also provide valuable information for clinical therapeutic articular cartilage repair, possibly preventing long-term degeneration of the treated site.

Results

Distribution and growth of hADSC in porous chitosan-GA scaffolds

The chitosan scaffolds used in this study appeared as a soft and highly porous sponge-like cylinders (Fig. 1a). Pores were fairly uniform and showed irregular morphology (Fig. 1b), with porosity determined as $211 \pm 66 \mu\text{m}$ from image analysis (length of cross-section measurements using ImageJ, NIH). The pore size distribution of the scaffolds used was overall evenly distributed and isotropic as a result of an optimized freeze-drying process (43). Mechanical properties could not be measured directly, as compression forces were below the range of our equipment, but they can be considered similar as described in other publications, as reviewed e.g. by Levengood et al. 2014 [49]. Values between 0.3 MPa tensile strength and 15.7 kPa [50] are given. After lyophilization, and especially with glutaraldehyde-crosslinking, the material does not swell in medium and retains sufficient rigidity to transfer mechanical cues to the cells.

Cells appeared well attached after 24 h (Fig. 1d-g) and distributed throughout the scaffold. Despite static culture, hADSC continued to grow well in the entire construct, forming abundant matrix (Fig. 1h-k). Matrix formation was strong with both hTGF- β_3 and hTGF- β_3 + hBMP-6, with no obvious difference between both treatments. In comparison, cells cultured without growth-factors showed less proliferation and matrix development (Figs. 1, 2 and 3). By day 14, abundant fibrous matrix had already formed (Fig. 1l-o) and after 28 days, the scaffold structure had completely disappeared under the newly formed matrix (Fig. 1p-s). The development and the stimulating effect of the growth-factors did not


seem impaired in the inner pores as compared to the outer rim, as no differences were found in SEM analysis.

In order to evaluate cell viability and proliferation on the hADSCs-seeded scaffolds, a WST-1 test in combination with a PicoGreen assay was performed 24 h after cell seeding and subsequently after 7, 14 and 28 days of incubation. Both cell viability and cell number, as indicated by DNA amount, increased progressively over the 28 day incubation period, indicating a steady increase of cells in all experimental groups, with a characteristic decrease in slope after 14 days marking the onset of differentiation (Fig. 2). The course of both parameters was alike and there was no difference between CS cultures and those treated with additional BMP-6. From day 7, there was a clear gap between cultures with growth-factor medium and those with proliferation medium, which widened in the further course (Fig. 2). When differentiation starts, cells usually switch from multiplication to matrix production, so growth factors often inhibit proliferation as compared to normal media. In this case, however, both cell proliferation (Fig. 2b) and cellular activity (Fig. 2a) were significantly higher under the influence of differentiation medium.

Histological and immunofluorescent analyses of matrix formation


The quality of the matrix formed was analyzed using Alcian blue staining for cartilage GAG in both scaffold (Fig. 3) and pellet cultures (Fig. 4). A clear enhancement of Alcian blue positive matrix formation by the application of growth factors was observed in the scaffolds (Fig. 3) supported by the histomorphometrical assessment (Fig. 5). The matrix was distributed throughout the scaffold with both treatments, with regional differences in density that are commonly observed after *in vitro* culture without mechanical stimulation at this stage.

A different picture arose for cell pellets. Pellet culture mimics cartilage nodule formation, giving a natural environment for chondrocyte differentiation, thus reliably leading to some form of cartilage formation in most cases. Accordingly, a certain amount of Alcian-positive matrix was found after culture in normal medium (Fig. 4d). Pellets cultured with hTGF- β_3 reach the same size, but had a much higher cellular density, coalescing with a heterogeneous histological picture (Fig. 4b), while the combination with hBMP-6 lead to much larger pellets with more matrix surrounding the cells (Fig. 4c). Although the pellets were not immunostained, the Alcian blue results (Fig. 4e, f) can be interpreted such that with hTGF- β_3 only, a very heterogeneous, partly condensed, partly hypertrophic tissue was formed, while the mature parts of pellets cultivated with hBMP-6 show strong and evenly distributed positive staining for cartilage matrix GAG.



Using immunofluorescence for a more detailed analysis of the matrix formed, the deposition of aggrecan (ACAN), an important and specific component of cartilage matrix, appeared to be slightly higher with hTGF- β_3 treatment only (Fig. 6). No ACAN was expressed without growth factors. The quality of tissue engineered cartilage is strongly defined by the relation of collagen II to collagen I formation. Collagen I does not belong to functional hyaline cartilage, with collagen II fibers giving the basic framework of the cartilage matrix. Here, almost no collagen II was found when no growth factors were


applied (Fig. 7), but also no collagen I (Fig. 8). Because proliferating chondrocytes usually form some amount of collagen I matrix and to exclude antibody functionality, immunohistochemical staining was performed (Suppl. Fig. 1) to validate collagen I results. A weak signal was detected in both normal proliferation medium and hTGF- β_3 at day 14 and 28 (Suppl. Fig. 1B, C, E, F) yet remained absent throughout hTGF- β_3 + hBMP-6 groups. It is therefore probable that the background noise from scaffold absorbing the immunofluorescent signal is affecting the detection of the collagen I and not the




antibody itself. Abundant collagen II could be found with hTGF- β_3 treatment, whereas the addition of hBMP-6 seemed to reduce the amount of this protein by day 28 (Fig. 7). Collagen X (Suppl. Fig. 2) was not detected in control and treatment groups.

The differences between chitosan-scaffold and the pellet culture were striking. Embedded in the polysaccharide, hADSC respond to both growth-factor

regimes with abundant matrix formation, with no differences in distribution and amount of Alcian-blue positive matrix and even a stronger formation of collagen II under hTGF- β_3 only. In pellet culture, the hADSC remain limited in matrix formation without additional hBMP-6, forming a heterogeneous tissue with apparently hypertrophic regions. The immunofluorescent matrix analysis has given unclear results







in this case. In order to monitor more clearly the differences gene expression was employed.

qRT-PCR of in vitro chondrogenic differentiation

To evaluate chondrogenic gene expression between the NS, CS, CS + hBMP-6, NP, CP and CP + hBMP-6 groups, relative qRT-PCR gene analysis was performed

on in vitro samples, monitoring the relative change in transcription of *ACAN*, *COL1A1*, *COL2A1*, *COL10A1*, *SOX9* and *COMP*. The results represent a snapshot of the above genes at day 7, 14 and 28 after culturing with standard chondrogenic, modified chondrogenic induction medium or normal medium in chitosan-based scaffolds seeded with hADSCs or in the form of a 3D





pellet. The results have been normalized to four reference genes (*ACTB*, *RPLP0*, *TBP*, *POLR2e*), expressed as \log_{10} CNRQ (calibrated normalized relative quantities, CNRQ). Relative expression of every gene in different groups but at the same time point is shown in Suppl. Fig. 3, whereas of every gene at different time points but in the same group is shown in Fig. 9.

The hyaline cartilage matrix *ACAN* and *COL2A1* expressions were found to be up-regulated in all groups (Fig. 9a, c) and increased significantly by day 28 in both pellets and cell-scaffold constructs treated with either chondrogenic medium ($p < 0.05$) (Fig. 9a, c). *ACAN* was much higher in all growth factor- (GF-) treated groups and collagen II in both GF-treated scaffold cultures, and both increased in expression with culture time (Fig. 9a, c). Interestingly, for chitosan-scaffold cultures, both genes showed a greater increase in expression under either GF-treatment, decreasing in normal medium, whilst in pellet culture, *ACAN* slightly increased and *COL2A1* remained constant over time in normal medium, with no significant increase of the latter under hTGF- β_3 treatment. With additional hBMP-6, pellets expressed slightly

more *COL2A1* on day 14, but significantly less on day 28.

The cartilage-oligomeric matrix protein (*COMP*) is an important regulator of matrix formation; the nuclear transcription factor *SOX9* is considered the central orchestrating signaling molecule of cartilage differentiation. Both clearly responded to growth-factor treatment, more clearly so for scaffold cultures. *COMP* and *SOX9* were both upregulated in CS group at all-time points and the expression increased significantly by day 14, greatly exceeding values for pellets, but decreased slightly at day 28 (Fig. 9e, f), whereas in the CS + hBMP-6 groups, *COMP* was upregulated briefly at day 7 after which it significantly decreased by day 28 (Fig. 9e, f). Both genes were more strongly expressed with time in pellet cultures, *COMP* remaining downregulated in proliferative and becoming slightly upregulated in hTGF- β_3 medium, yet further downregulated with hBMP-6 (Fig. 9e, f). *SOX9* expression in pellets with normal medium was downregulated at day 7 and 14, but upregulated at day 28, whereas being downregulated at all-time points in normal medium with scaffolds group (Fig. 9e, f). As in




Fig. 7 Immunofluorescence staining of collagen type II (green) at day 7, 14 and 28 in chitosan scaffolds with hADSCs cultured in normal (NS), standard chondrogenic (CS) or modified chondrogenic + hBMP-6 medium (CS + hBMP-6). The chitosan scaffolds fluoresced yellow, whereas living cell nuclei fluoresced blue. Magnification set a 10x

scaffolds, *COMP* expression in pellets was significantly higher in chondrogenic groups at all-time points, while contrary to the former, *SOX9* was not consistently so, expression levels being more or less equal for all treatments in pellets on day 28 (Suppl. Fig. 3E, F).

When analyzing cartilage matrix formation, it is insufficient to look at existing expression of positive markers, as these are common also in matrix destined for hypertrophy and mineralization. Here, *COL1A1* and *COL10A1* were included as negative markers for differentiation towards articular cartilage, as they are indicators for endochondral bone formation [54, 55]. The qRT-PCR results for those genes showed some similarities with the optical impression of histological images (Suppl. Figs. 1, 2).

For the fibrous tissue component *COL1A1* was generally downregulated, yet slowly increasing in pellet cultures, higher in scaffolds with normal medium but clearly upregulated in scaffolds and pellets with hTGF- β_3 treatment (Suppl. Fig. 3B). Similar to dedifferentiation processes in 2D culture, it increased with time in all treatments except for scaffolds supplemented with

hTGF- β_3 + hBMP-6, where it was clearly and progressively downregulated (Fig. 9b). In pellet culture, downregulation of *COL1A1* was even stronger with hBMP-6, reaching the lowest level of all samples.

COL10A1 expression was downregulated in both pellet cultures and scaffolds cultures with normal medium (Suppl. Fig. 3D), but intriguingly decreasing in expression in NP only, increasing towards day 28 in the other two (Fig. 9d). Similar to collagen I, this clear signal of beginning hypertrophy was increased in pellets by hTGF- β_3 treatment in hADSC. Most striking in the expression pattern of *COL10A1* however is the difference between pure hTGF- β_3 treatment and the addition of hBMP-6 in scaffold cultures. The expression level rose to the point of upregulation with hTGF- β_3 , but remained low with additional hBMP-6. There was no such contrasting influence on chondrocytes in pellet culture.

In interaction with the chitosan matrix, hTGF- β_3 had a stronger effect on chondrogenic gene expression in hADSC, but also induced hypertrophy, part of which was rescued by adding hBMP-6. Although histological analysis revealed stronger differences between growth




Fig. 8 Immunofluorescence staining of collagen type I (green) at day 7, 14 and 28 in chitosan scaffolds with hADSCs cultured in normal (NS), standard chondrogenic (CS) or modified chondrogenic + hBMP-6 medium (CS + hBMP-6). The chitosan scaffolds fluoresced yellow, whereas living cell nuclei fluoresced blue. Magnification set a 10x

factors samples with and without additional hBMP-6 for pellets and not for scaffolds, qRT-PCR showed an effect of hTGF- β_3 on the expression of *COL10A1* in scaffolds that was not found in pellet cultures. Moreover, the influence of hTGF- β_3 medium on the expression of *COL2A1*, *COL1A1*, *COMP* and *SOX9* was much stronger in scaffolds, while the “rescuing” effect of additional hBMP-6 was much weaker for *COL1A1* and *COMP*.

Discussion

Articular cartilage regeneration remains a challenging clinical task [2, 4, 51], despite several promising approaches using adapted scaffold materials and a combination of stem cells with growth factors [52–56]. Bio-materials used in cartilage tissue engineering need to be highly biocompatible, biodegradable, as well as possessing the adequate biomechanical properties and geometric organization that further support cell attachment, proliferation and differentiation [17–19]. As such, the ideal scaffold should mimic the extracellular cartilage matrix, in both form and function, and retain the

phenotype of differentiated stem cells [57]. One such material is chitosan, a polysaccharide derived from the exoskeleton of arthropods, which has shown to be one of the more advantageous substances that has been widely investigated and used in various derivative forms in tissue engineering as well as for clinical applications [58]. In particular, scaffolds composed of poly(lactic-co-glycolic acid) (PLGA)/chitosan have been shown to support chondrocyte development from hADSCs and to form articular cartilage in a lagomorph model over 12 weeks [20, 59, 60]. Compared to chondrocytes isolated from mature cartilage and BM-MSCs isolated from bone marrow, hADSCs can be harvested in large amounts and are readily accessible [61]. Human ADSCs can be expanded in stable cultures of undifferentiated cells and can easily be differentiated into chondrocyte-like cells in vitro under specific culture conditions, maintaining the chondrogenic phenotype even in vivo after transplantation [62, 63]. However, as shown in our previous study [31], the use of hADSCs cultured on a pure, elastic and porous scaffold composed of glutaraldehyde-cross-




Fig. 9 Relative gene expression quantity of (a) *ACAN*, (b) *COL1A1*, (c) *COL2A1*, (d) *COL10A1*, (e) *COMP* and (f) *SOX9* between all culture groups (N = normal medium; C = chondrogenic medium, P = 3D Pellet; S = chitosan scaffolds). (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). The baseline 0 represents untreated hADSCs in monolayer, which was the normalisation factor

linked chitosan is inadequate for articular cartilage regeneration. Without the correct soluble signals, the biomimetic matrices can only assist new tissue formation relying on additional morphogens to facilitate faster tissue growth in the regeneration for large defects. Yet, the correct signaling proteins needed to for the formation of stable hyaline cartilage (reviewed in [64]) within

biomaterials have not been properly identified. Cartilage regeneration approaches using stem cells generate chondrocytes that, whilst depositing a chondrogenic-like matrix, have a strong tendency to either deposit large amounts of collagen I in a fibrous tissue or, even more often, go into hypertrophy in a mineralizing matrix that initiates endochondral ossification [65]. When following

up on attempts to illuminate underlying mechanisms and improve the clinical situation, methodological inconsistencies appear, producing non-standardized and non-reproducible results. Indeed, some morphogens such as the hTGF- β_3 , accepted as a common chondrogenic stem cell differentiation morphogen [66], have been shown to have undergone evolutionary and functional variation, especially in regard to induction of bone formation between different animal models [67, 68]. It is therefore not clear if hTGF- β_3 can truly form “articular cartilage” on biomaterial carriers or if a synergy with at least one more morphogen, such as used in previous studies with hBMP-6, is required [31, 43] to achieve this. This question was therefore assessed in the present study in which we sought to validate our previous results that hADSCs cultured in chitosan only form hyaline matrix in the presence of hTGF- β_3 + hBMP-6, proving that a proper morphogen combination in the right carrier matrix is necessary to form the correct tissue type. It was further the intention to show that hTGF- β_3 alone does not support hyaline articular formation but leads to hypertrophy that finally ends in bone formation, as suggested in studies by Ripamonti et al. [40–42] and Klar et al. [69].

The in vitro viability, proliferation and differentiation capacity of hADSCs cultivated in lyophilized scaffolds of glutaraldehyde-cross-linked chitosan, as previously observed, increased stably with culture time over the 28 days. The scaffolds with their porous structure enabled viability, migration and proliferation of hADSCs. Results from the Live/Dead assay demonstrated that the hADSCs exhibited very good adhesion and biocompatibility on the biomaterial. Comparing the results from this assay from 14 days onward between chondrogenic and control groups, a strongly enhanced cell proliferation in chitosan scaffolds with chondrogenic differentiation medium demonstrated a positive interaction of the carrier with the morphogens. Scanning electron microscopy clearly showed cells colonizing the scaffolds, forming a lush fibrous matrix with denser layers occurring on the periphery of the device by 28 days. This effect has to be attributed to the influence of hTGF- β_3 , which has been shown to stimulate chondrocyte proliferation e.g. in rabbit articular chondrocytes [70], a mechanism has recently been proposed for rat chondrocytes [71]. This could be one aspect why TGF- β alone is not suited to induce cartilage formation. BMP-6, on the contrary, has been demonstrated to reduce proliferation by induction of differentiation [72], a process opposed to cell growth in articular cartilage. The overall increased growth may be indicative of a still to large influence of TGF- β , the balance between the two factors still has to be adjusted for successful hyaline cartilage formation.

A strong indication for the chitosan’s capacity to support the induction of chondrogenesis by growth factors was the detection of both glycosaminoglycan (GAG) synthesis, a part of the extracellular matrix of cartilage, as well as collagen type II transcription and translation together with *ACAN* and *SOX9* upregulation. Human ADSCs cultured on chitosan scaffolds with normal medium did not show substantial formation of GAGs compared to both those cultured in standard or modified chondrogenic medium and the corresponding 3D pellet controls. This was in accordance with results of immunofluorescent, immunohistochemical, histomorphometrical analysis and qRT-PCR assays. *COL2A1* was significantly down-regulated by day 28 in the NS group with *ACAN* and *SOX9* also decreasing substantially compared to the same normal medium group with 3D-pelleted hADSCs. The relative gene expression assay of chondrogenic differentiation markers further supported this finding where *ACAN* and *SOX9* expression increased in both chitosan groups irrelevant of medium type, even though *COL2A1* was only significantly upregulated in chondrogenic medium. The transcription factor *SOX9* is an early marker for chondrogenesis that regulates collagen type II and cartilage-specific matrix synthesis by activating the *COL2A1* and *ACAN* [73, 74]. Another study previously demonstrated that *SOX9* was also expressed in proliferating and pre-hypertrophic chondrocytes, but is downregulated in hypertrophic chondrocytes [75]. From the present results, it appears that the chitosan scaffold on its own can induce hADSCs to undergo differentiation towards a cartilage lineage but cannot form a cartilage matrix without the addition of a subsequent stimulant, which was the case for the CS, CS + hBMP-6 and CP groups where hTGF- β_3 alone or in combination with hBMP-6 was used. Indeed, through the addition of hBMP-6, *SOX9* significantly increased and was greater than the standard CS group, a pattern that remained consistent for all gene types including *ACAN* and *COL2A1*.

Immunofluorescence staining of collagen type II and aggrecan as well as histological staining with Alcian blue for GAG confirmed that the groups treated with hTGF- β_3 , CP and CS and hTGF- β_3 + hBMP-6 showed an increase both on the translational and transcriptional levels of most cartilage relevant markers. In particular in the chitosan group, histological and immunofluorescence staining demonstrated that GAG and collagen type II synthesis was significantly increased during the in vitro culture over 28 days, indicating that indeed this biomaterial supports the formation of specific matrices in this case those consisting of collagen type II as is the case for cartilage. *ACAN*, *COL2A1* and *SOX9* expression levels all increased significantly, suggesting that the chitosan scaffold alone provides a far superior

microenvironment that allows for the adhesion, proliferation and differentiation of cells under the influence of both chondrogenic medium types, especially with a combination of hBMP-6 and hTGF- β_3 .

However, one crucial question in cartilage regeneration in vitro is whether the matrix formed is hyaline or contains significant amounts of collagen I, and if it is hyaline matrix does it develop towards stable articular cartilage or rather progresses towards hypertrophy and mineralization. *ACAN*, *COL2A1* and *SOX9* are markers that are generally utilized to monitor if any cartilage formation had occurred irrelevant of the type [76–78]. *COL1A1*, *COL10A1* and *COMP* on the other hand are classical markers to further differentiate what type of cartilage is being formed [77, 79, 80]. Articular cartilage has superior load-bearing and mechanical properties and is free of collagen I [81, 82], while hyaline cartilage formed during endochondral ossification of embryogenesis for certain skeletal bones, is characterized by the early appearance of collagen X [83]. In our study, collagen type I immunofluorescence/histochemical staining was minimally detected in NS and CS but not CS + hBMP-6 at day 7, 14 and 28, strengthening our previous articular hyaline cartilage formation discoveries [31]. This corroborated with the gene expression patterns for *COL1A1* suggesting that cultures were not purely articular and already programmed towards hypertrophy, except for the chitosan scaffolds cultured in the modified hTGF- β_3 + hBMP-6, where these genes were all significantly and consistently down-regulated (Fig. 9b, d). Whilst *COL10A1* was downregulated with immunohistochemical staining validating gene expression results, *COL1A1* decreased significantly in the standard chondrogenic chitosan or whilst in the pellet culture. *COL1A1* remained high and only after day 28 had minimally decreased, but not significantly, as is expected during articular cartilage formation. Whilst stem cells, in the absence of a carrier matrix, could have a higher probability to become articular chondrocytes in the presence of hTGF- β_3 , the latter's cartilage formation potential is far too low to be considered on its own for large scale in vivo cartilage repair. It appeared that the chitosan scaffolds creates a superior environment to support large scale cartilage matrix production, provided that the correct morphogens are present to facilitate the correct matrix formation [13, 14]. This was made evident by the expression of *COMP*, a pentameric non-collagenous matrix protein expressed primarily in articular cartilage. It is reported to regulate both chondrogenesis and endochondral ossification, including stabilizing the ECM of articular cartilage, by maintaining the structural integrity through its interaction with *ACAN*, *COL2A1*, *COL10A1* and fibronectin [84–86]. Results shown here in part recapitulate our previous observations [31], with *COMP*

being downregulated as compared to unstimulated hADSCs in the monolayer in all groups except for the CS and CS + hBMP-6 groups cultured for 7 (CS + hBMP-6 and CS) and 14 (CS only) days. During the first 7 days, *COMP* expression was not different between CS and CS + hBMP-6. Only by Day 14, *COMP* in the CS + hBMP-6 was downregulated here with the CS group only following this trend by day 28. This suggests that TGF- β_3 on its own enhances the production of an extracellular matrix that is however not articular in nature as evidence by the expression of *COL1A1* and *COL10A1*. At Day 28, *COMP* group decreased in its expression pattern in both CS and CS + hBMP-6 groups, similar to observations reported before [87]. We suggest that the balance between the TGF- β_3 and BMP-6 was not adjusted well enough to avoid the decrease in the medium containing both growth-factors. *COMP* is a matrix element with several important functions, among which there is an important role in adipose tissue [88], the source of the stem cells used. Possibly, depending on the donor, cells had maintained a high *COMP* expression and the observed downregulation was indeed a regulation to normal levels.

Indeed, the results further demonstrated clearly that hTGF- β_3 alone is not a suitable morphogen for articular cartilage formation as has been suggested before but ignored for most part in the tissue engineering field [89–91]. Our results unequivocally demonstrated that hTGF- β_3 alone causes endochondral cartilage formation tending towards ossification rather than true articular cartilage development, unless it is counteracted or synergizes with another TGF- β supergene family member(s) that modulate better the process of articular cartilage formation, here hBMP-6. Although the current literature does not explicitly state this, as it generalizes more on the term chondrogenesis [47, 48], we can now with a better degree of certainty claim that the synergistic effect of hBMP-6 with hTGF- β_3 causes “articular” chondrogenesis.

The TGF- β isoforms have previously been established to supposedly possess good “chondrogenic differentiation potentials” when utilizing MSCs [66] as much of the TGF- β isoforms are present in articular cartilage with even miniscule quantities of active TGF- β being a potent stimulant for proteoglycan and type II collagen synthesis. This was again substantiated in the present study where 10 ng/ml of hTGF- β_3 promoted significant chondrocyte differentiation and resulted in increased type 2 collagen transcription and translation [16] but in hADSCs. Indeed, most of the previous studies on the articular cartilage differentiation potential were based on MSCs, and were solely focused on whether TGF- β isoforms also possess similar chondrogenic differentiation capacities as ADSCs [92]. Whilst in vitro traits of TGF-

β isoforms at inducing articular chondrogenesis show increased *COL2A1*, *SOX9*, *ACAN* and reduced *COL1A1* expressions [93, 94], in vivo based research remains problematic; despite extensive investigations demonstrating the potential of MSCs to regenerate cartilage, the latter degenerates quickly in vivo after a certain number of weeks, leading to ossification rather than maintaining articular cartilage state [60, 94]. The question must therefore be asked whether the matrix was articular to begin with. Indeed, in the present study similar gene expression results with respect to *COL2A1*, *SOX9* and *ACAN* were produced in hADSCs too, supporting the concept that TGF- β isoforms, especially hTGF- β_3 , can induce a form of chondrogenic differentiation also in these stem cells [92]. However, the exception of *COL1A1* at day 28 in both pelleted hADSCs in the absence of standard chondrogenic medium (Fig. 9b) and the enhanced expression of *COL1A1* and *COL10A1* in the biomimetic chitosan scaffolds, replicating in part an in vivo environment, would suggest that previous theories are not quite as accurate, possibly due to outdated qPCR techniques [65, 69], or that not all stem cells share equal cellular differentiation capabilities to undergo transformation into certain cell types for the formation of specialized tissue matrices. Even in studies using certain BMP members such as BMP-7, BMP-2 and BMP-4 alone as part of chondrogenic medium instead of a TGF- β isoform, promising in vitro results were achieved [95–98], but for in vivo applications the newly formed cartilage structures revert to the typical ossification of endochondral bone formation [99]. This suggests that single morphogen applications are not sufficient at achieving the correct cellular response to yield correct tissue formation especially where articular cartilage formation is concerned. Only by combining two morphogens of the TGF- β supergene family members, here hTGF- β_3 with hBMP-6, can proper articular cartilage formation be re-established to produce stable hyaline cartilage, as shown in the present study and previously postulated by [43] and us [31, 69, 100].

It therefore appears that, despite the results proving that chitosan is a suitable carrier with a potential to support articular cartilage formation, the appropriate morphogens are the key driving force for the induction of correct matrix formation. In this model, even in the presence of a suitable carrier matrix, the correct “keys” are needed to open the locking mechanism of correct tissue morphogenesis. Our findings confirm that hTGF- β_3 alone is not suited as an articular cartilage-inducing morphogen for hADSCs. Previous concepts may need to be re-evaluated in light of modern molecular techniques based on advanced qRT-PCR techniques as stated by Bustin et al. [101] or Next Generation Sequencing that will provide detailed molecular mechanistic insights into

the underlying mechanisms of single TGF- β supergene family members and multiple combined morphogen members. Such efforts will help properly identify how these factors act on causing stem cell differentiation towards articular chondrocytes. Future research on the regulation of these proteins and the identification of intrinsic cellular pathways leading to proper articular cartilage formation are therefore critical to avoid errors or misinterpretations that lead to further delays in clinical applications. Future articular cartilage regeneration procedures should consider including hTGF- β_3 + hBMP-6, and find ways to maintain the presence of these morphogens for at least 28 days or more. This, if achieved, would very likely lead to articular cartilage matrix formation that does not degenerate in the future to fibrocartilage or osteogenic tissue.

Conclusion

Chitosan remains a viable and highly beneficial biomaterial that has the capacity to support extensive differentiation of stem cells into chondrocytes, but may tend towards ossification unless the correct signals are present. Human ADSCs have been shown to be a competitive alternative stem cell type that has many excellent qualities to differentiate into the appropriate cell types including chondrocytes, provided that the correct signaling molecules are present. Human TGF- β_3 , however, does not properly facilitate articular cartilage chondrocyte differentiation in hADSCs in pellet or on a biomaterial, rather tending towards inducing endochondral cartilage formation that will in the long run ossify. Moreover, our results confirmed that only by using an optimized morphogen mixture together with a suited carrier matrix may provide a more efficient environment at regenerating articular cartilage defects than existing strategies, as hBMP-6 with hTGF- β_3 maintains an articular cartilage formation milieu.

Methods

Biomaterial scaffold design

Porous sponges were manufactured by lyophilization of glutaraldehyde-cross-linked 0.5% wt/vol chitosan hydrogels as described previously [31]. Briefly, chitosan with a 95% degree of deacetylation (Heppe Medical, Halle, Germany) was dissolved at 1% wt/vol in 0.1 N HCl with pH 1. Using 1 N NaOH, the pH was carefully adjusted to 5 under constant stirring and dropwise addition of the base. Hydrogels were formed by mixing 1 ml of chitosan solution with 1 ml aqueous 1% glutaraldehyde solution (Sigma-Aldrich, St. Louis, MI, USA) in hollow disc shapes with a diameter of 15 mm. After gelation, samples were frozen at -32°C using polystyrene insulation to control freezing rate. Frozen samples were then freeze-dried at -50°C under vacuum using an Alpha 1–

4 LD system (Christ, Osterode am Harz, Germany). The dry scaffolds were then trimmed on both ends to a final height of 8 mm with a microtomic blade and gamma-sterilized at ca. 27 kGy.

The resulting scaffold morphologies were examined using a VHX-5000 3D digital microscope (Keyence, Osaka, Japan) and software VHX-5000 Ver. 1.6.1.0 / System Ver. 1.04 (Keyence). The microstructure of the scaffolds was observed by scanning electron microscopy (SEM) (JEOL JSM-6360LV, Tokyo, Japan).

Isolation and culture of hADSCs

Human ADSCs were isolated, as previously described [31, 102], from subcutaneous adipose tissue from 4 patients of different sex and age (age 31–80, BMI 29–52) that was acquired from the Biobank of the University Hospital of Munich Germany which operates in accordance to the European Union compliant ethical and legal framework of the Human Tissue and Cell Research Foundation (<http://www.htcr.org>). The research was approved by the Human Ethics Committee of the Faculty of Medicine at the University of Munich and the Bavarian State Medical Association. Briefly, harvested adipose tissue were rinsed with phosphate buffered saline (PBS) containing 180 IU/ml penicillin/streptomycin and 0.75 µg/ml amphotericin B (Biochrom, Berlin, Germany), after which the tissue was cut into small fragments and digested with 0.2% collagenase A solution (Sigma-Aldrich) in DMEM (Gibco, Waltham, MA, USA) at 37 °C. Then 15% fetal calf serum (FCS; Sigma-Aldrich) supplemented culture medium was added, after which the mixture was resuspended, filtered through 100 µm sieves and centrifuged at 400 g for 10 min at room temperature (RT). The pellet containing hADSCs was resuspended with fresh growth medium (DMEM, 15% FCS, 60 IU/ml penicillin/streptomycin), seeded in a T-75 culture flask and cultured at 37 °C with 5% CO₂ for 24 h. Subsequently, the adhered cells were washed with PBS and 20 ml of fresh growth medium was added. The medium was replaced every 3 days. Human ADSCs used in this study were used at passage 4.

Cell seeding onto chitosan sponges and in vitro chondrogenic differentiation

The dry scaffolds were placed carefully in a 12-well plate (Thermo fisher scientific, Waltham, MA, USA) and covered with 2 ml normal growth medium (high-glucose DMEM 4.5 g/L D-glucose, 110 µg/ml Pyruvate; Gibco, supplemented with 10% FCS, 60 IU/ml penicillin/streptomycin). Scaffolds were then incubated at 37 °C with 5% CO₂ for 6 h after which the medium was changed and left to incubate overnight. Human ADSCs (~90% confluent) were digested with trypsin/EDTA and counted and resuspended at a concentration of $\sim 1 \times$

10^7 /ml. To seed the cells on the chitosan scaffolds, the old medium was removed and 100 µl of cell suspension was pipetted evenly onto each. Scaffolds with cells were incubated at 37 °C at 5% CO₂ for 1 h to allow for cell attachment, whereupon 2 ml of normal growth medium was added to each well and incubated overnight. The following morning (Day1), the cell-seeded scaffolds were transferred into either normal growth medium (Normal + Scaffold or “NS”; $n = 9$), standard chondrogenic (hTGF- β_3) medium (Chondrogenic + Scaffold or “CS”; $n = 9$) or modified chondrogenic (hTGF- β_3 + hBMP-6) medium (Chondrogenic + hBMP-6 + Scaffold or “CS + hBMP-6”; $n = 9$). The standard chondrogenic medium was normal growth medium supplemented with 10 ng/ml recombinant human TGF- β_3 (R&D Systems, Minneapolis, MN, USA), 100 nM dexamethasone (Sigma-Aldrich), 50 µg/ml L-ascorbic acid-2-phosphate (Sigma-Aldrich), 40 µg/ml L-proline (Sigma-Aldrich) and ITS+1 (Sigma-Aldrich; final concentrations: 10 mg/L insulin, 5.5 mg/L transferrin, 4.7 µg/ml linoleic acid, 0.5 mg/ml bovine serum albumin and 5 µg/L selenium). Chondrogenic + hBMP-6 medium was the standard chondrogenic medium as described above + 10 ng/ml recombinant hBMP-6 [22]. The cell-seeded constructs cultured with normal growth medium (NS) were considered as scaffold control group. Samples were cultured for 7, 14, and 28 days and medium was replaced every 3 days.

Pellet culture and chondrogenic differentiation

Pellet culture was used as comparable, scaffold-free 3D culture control [103], to investigate both scaffold and culture medium influence on stem cell differentiation and matrix formation. Human ADSCs from the fourth passage were resuspended at a concentration of 2.5×10^5 cells per ml in normal growth medium (see above). Two milliliters of the cell suspension containing 5×10^5 hADSCs were transferred into a 15 mL polypropylene conical tube and centrifuged at 500 x g for 5 min to allow for 3D cell pellet formation. The 3D pelleted cells were then incubated overnight at 37 °C with 5% CO₂ with loosened caps to permit gas exchange. Spheroid aggregates formed at the bottom of each tube. Next day (Day1), the culture medium was replaced with 2 ml of fresh growth medium (Normal + Pellet or “NP”; $n = 9$), standard chondrogenic (hTGF- β_3) medium (Chondrogenic + Pellet or “CP”; $n = 9$) or modified chondrogenic (hTGF- β_3 + hBMP-6) medium (Chondrogenic + hBMP-6 + Scaffold or “CS + hBMP-6”; $n = 9$) carefully so as not to resuspend the cell pellet. The 3D pellet medium was changed every 3 days, and 3D cell pellets were cultured for 7, 14, and 28 days prior to harvest and processing for analysis. Cells cultured in normal growth medium were used as the pellet control group.

Scanning electron microscopy (SEM)

Scanning electron microscopy was performed as previously described [31]. In order to see the matrix development progression of hADSCs on the scaffolds treated with modified chondrogenic medium, a scaffold was randomly chosen and cultured for 1, 7, 14 and 28 days. Upon harvest, the cell-scaffold constructs were washed with PBS and fixed in 2.5% glutaraldehyde in PBS overnight at 4 °C. The constructs were then stained with 1% osmium tetroxide, dehydrated in a graded series of alcohols, dehydrated using the critical point drying method, and coated with gold. The samples were examined with a scanning electron microscope (SEM) at an accelerating voltage of 20 kV (Carl Zeiss EVO LS 10, Oberkochen, Germany).

Cell viability and proliferation assay

The viability and proliferation of hADSCs cultured in the CHI and CHI/HA scaffolds were evaluated by means of a water-soluble tetrazolium-1 (WST-1) reagent (Roche, Basel, Swiss) in combination with Quant-iT™ PicoGreen dsDNA Kit (Invitrogen, California, USA) at day 1 and subsequently at day 7, 14, or 28, as described previously [31]. Briefly, the CHI and CHI/HA scaffolds with the hADSCs were transferred to a new 24-well plate and washed twice with PBS after which 0.5 ml fresh normal growth medium containing WST-1 at 10:1 (v/v) was added to each well and incubated for 3 h at 37 °C at 5% CO₂. The absorbance of the WST-1/medium mixture was read at 450 nm using a Synergy HT microplate reader and Gen 5 2.03 software (BioTek, Vermont, USA) in a 96-well plate. The same scaffolds were used for the PicoGreen dsDNA Assay. Here The 1% PSCs were washed twice with PBS. According to the manufacturer's protocol, the cells were lysed from the scaffold and DNA standards were mixed with TE-buffer and subsequently with Quant-iT PicoGreen dsDNA reagent. The samples were excited at 480 nm and the fluorescence emission intensity was measured at 520 nm using a Synergy HT microplate reader and Gen 5 2.03 software (BioTek).

Cell survival in the scaffold

The effects of chitosan scaffolds on cell survival in both normal and altered chondrogenic differentiation medium including normal growth medium were studied by using a Live/Dead assay, as described previously [31]. At day 1, 7, 14 and 28, the cell-scaffold constructs were stained with a LIVE/DEAD Viability/Cytotoxicity Kit (Invitrogen). Briefly, cell-scaffold constructs were rinsed with PBS and incubated in staining solution containing Calcein AM and Ethidium homodimer-1 (EthD-1) at room temperature for 30 min, followed by washing with PBS. Then the constructs were examined by fluorescence microscopy (Carl

Zeiss). Healthy cells fluoresce green, while the nucleus of dead cells fluoresced red [89].

Histological, immune-fluorescence and -histochemical analysis

As described previously [31], after 7, 14 and 28 days of culture the cell-scaffolds and 28 day 3D cell pellets were fixed in 4% paraformaldehyde for 30 min at room temperature. The 1% chitosan scaffolds with cells were dehydrated through a graded series of alcohols into paraffin, whereas the 3D cell pellet cultures were embedded in a Tissue-Tek O.C.T.™ compound (Sakura Finetek Germany, Staufen, Germany) and frozen in liquid nitrogen. Following this, 10 μm thick sections were cut using either a Microtome (Leica, Wetzlar, Germany), for paraffin specimens, or a CM 3050 cryomicrotome (Leica), for the cryogenic embedded specimens. To visualize tissue morphology and cartilage matrix formation, sections were stained with Alcian blue at pH 2.5 for glycosaminoglycan (GAG) content formation. All stained sections were analyzed with a PreciPoint M8 Digital Microscope & Scanner (PreciPoint GmbH, Freising, Germany).

To determine the quality of the matrix composition, chitosan scaffold cultures within the NS, CS and CS + hBMP-6 groups were immunofluorescently stained for collagen I, collagen II, aggrecan and immunohistochemically for collagen I and collagen X (for validation purposes). Briefly, paraffin sections were incubated with primary antibodies (all from Abcam, Cambridge, UK) for either collagen type I (1:300; Cat# ab34710), collagen type II (1:200; Cat# ab34712), aggrecan (1:300; Cat# ab3778) and collagen type X (1: 200; Cat# ab58632) at 4 °C overnight. The antibodies were diluted with antibody dilution buffer (DCS, Germany). For negative controls, the first antibody was omitted. The slides were then incubated with the conjugated secondary antibody (Abcam, Cambridge, UK) for 1 h at room temperature. For immunofluorescence nuclei of cells were then stained for 8 min with Hoechst 33342 (Life Technologies, Carlsbad, USA). The slides for immunofluorescence were mounted with Fluoromount W (Serva Electrophoresis, Heidelberg, Germany) air-dried and stored in darkness at 4 °C, whereas those for immunohistochemical assessment were mounted with chromogen AEC (DCS, Germany). Fluorescence microscopy was then performed with a Zeiss Axioskop 40 equipped with appropriate filter sets and AxioCam MRC 5 (Carl Zeiss, Munich, Germany). Images were obtained with Axio Vision, Rel. 4.9 (Carl Zeiss, Munich, Germany). Exposure time was kept constant for the samples where fluorescence intensity was to be compared. On the other hand, immunohistochemical stained sections were captured using PreciPoint M8 Digital Microscope & Scanner

(PeciPoint) with AEC stained tissue staining as a wine-reddish color.

Histomorphometrical assessment Alcian blue GAG content

Histological cuts were processed for Alcian blue positive matrix formation using a combination of image processing codes based on ImageJ (<https://imagej.nih.gov/ij/>). The pictures were first treated for noise using a Gaussian filter (kernel = 2.0, sigma = 0.5), and then segmented with a color threshold in the Red-Green-Blue color space, selected visually to isolate pixels stained with Alcian blue within the histological pictures and setting them to 1, while other region were set to 0. Image parts not within the specimen region were removed. The final %GAG content was calculated as the ratio of pixels within the Alcian blue positive region to the total amount of pixels within the image, after subtraction of the external region. A mean and standard deviation was calculated for each group at each time point, and a Student's T-Test was performed for statistical differences between groups and at each time point (significance if $p < 0.05$).

Quantitative real-time PCR (qRT-PCR)

As described previously [31], quantitative RT-PCR, according to the MIQE guidelines [101], was performed to determine the relative expression of the chondrogenic genes, *aggrecan (ACAN)*, *collagen type II (COL2A1)*, *cartilage oligomeric matrix protein (COMP)*, *SRY-box 9 (SOX9)* with *collagen type I (COL1A1)* and *collagen type X (COL10A1)* being incorporated to determine if cartilage matrix development was pure articular or progressing towards an endochondral ossification lineage. After 7, 14 and 28 days, total RNA was isolated using a modified RNA Trizol extraction procedure [104]. Briefly, 1 ml Trizol (Invitrogen) was added to cell material after which chloroform (Sigma-Aldrich) was added to permit separation of the RNA from the proteinaceous material.

After centrifugation the aqueous RNA containing phase was transferred to a fresh tube where the RNA was then precipitated out by adding Isopropanol (Sigma-Aldrich). After incubation at RT for 10 min samples were centrifuged at 16000 rpm over night at 4 °C, upon which RNA pellets were then washed with 75% Ethanol (Merck, Billerica MA, USA) and permitted to dry briefly to prevent alcohol contamination. After drying, total RNA was resuspended in 32 µl RNase free water (Gibco) after which the concentration and purity of the RNA was determined using a NanoDropTMLite spectrophotometer (Thermo Scientific) and quality assessed with a Bioanalyzer 2100 (Agilent Technologies). After RNA extraction approximately 1 µg of RNA was reverse transcribed into complementary DNA (cDNA) utilizing the QuantiTect Reverse Transcription cDNA Synthesis Kit (Qiagen, Germany).

Quantitative RT-PCR was then performed in duplicate, using the FastStart Essential DNA Green Master (Roche) on a Light Cycler 96 thermocycler (Roche). Each reaction mixture contained: 10 ng cDNA, 10 µM of each primer (Table 1), 2x FastStart Essential DNA Green Master and RNase-free water to a final reaction volume of 20 µl. The primers of six target genes were designed using Gene fisher v. 2.0 (<http://bibiserv.techfak.uni-bielefeld.de/genefisher2>) and optimized according to the MIQE Guidelines [101]. Use of GeNorm (<http://medgen.ugent.be/~jvdesomp/genorm/>) established that *TATA sequence binding protein (TBP)*, *succinate dehydrogenase complex flavoprotein subunit A (SDHA)*, *ribosomal protein lateral stalk subunit P0 (RPLP0)* and *Ribosomal Protein L13a (RPL13a)* were the most appropriate internal reference genes to use in this experiment. All amplified PCR products underwent sequencing (GATC Biotech, Constance, Germany) to confirm that the correct sequence had been amplified. Quantitative RT-PCR cycling conditions included a 3 min pre-incubation at 95 °C, followed by a three step amplification program of 40 cycles consisting of a denaturation, annealing and extension step set at

Table 1 Gene specific primers used for quantitative real-time PCR

Gene	Forward primer (5' - 3')	Reverse primer (3' - 5')	Accession Nr.	Amplicon Size (bp)
<i>COL2A1</i>	GCCCAGTTGGGAGTAAGT	CACCAGGATTGCCTTGAA	NM_001844.4	106
<i>COL1A1</i>	GCTGGTCCTCCAGGTGAA	GGGGACCAACAGGACCA	NM_000088.3	159
<i>COL10A1</i>	TGGCCTGCCTGACTTTA	AATGTCCAGTCACTGGA	NM_000493.3	151
<i>ACAN</i>	ACCCAAGGACTGGAATCT	CCTGATCCAGGTAGCCTT	NM_001135.3	149
<i>COMP</i>	TGCACCGACGTCAACGA	CCGGGTGTTGATGCACA	NM_000095.2	231
<i>SOX9</i>	GTGGCTGTAGTAGGAGCT	GCGAACGCACATCAAGA	NM_000346.3	155
<i>ACTB</i> (reference)	CTGCCCTGAGGCACTC	GTGCCAGGCGAGTGAT	NM_0011101.3	197
<i>RPLP0</i> (reference)	CAACCCAGCTCTGGAGA	CAGCTGGCACCTTATTGG	BC001834.2	116
<i>TBP</i> (reference)	CACTTCGTGCCCGAAAC	GCCAGTCTGGACTGTTCT	BC110341.1	121
<i>POLR2e</i> (reference)	CTATCTGGTGACCCAGGA	CTGCAGAAACTGCTCCA	J04965.1	322

95 °C for 10 s, 58 °C for 15 s and 72 °C for 30 s, respectively. Six target genes relative expression between samples was normalized to the four reference genes using the qbase+ software (<https://www.qbaseplus.com>). Data was further normalized to untreated hADSCs in monolayer.

Statistics

As described previously [31], data is presented as means \pm standard deviation (SD, $n = 9$) for the results of WST-1, PicoGreen and qPCR. Qbase+ software was used to analyze the data from qPCR. Microsoft Excel and Prism 5.02 software (GraphPad Software, San Diego, USA) were used for analyzing the data. An ANOVA and a Kruskal-Wallis test were performed to test for the overall effect of the variance using R software version 3.6.1 (SAS, Marlow, UK). The Students T-test was used post hoc for comparing groups of data. A $p < 0.05$, $p < 0.01$ and $p < 0.001$ were considered significant, highly or extremely significant, respectively. Statistical significance was indicated by * for $p < 0.05$, ** for $p < 0.01$ and *** for $p < 0.001$.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s12896-020-00641-y>.

Additional file 1: Supplementary Figure 1. Immunohistochemical staining of collagen type I (black arrows, wine red color) at day 7, 14 and 28 in chitosan scaffolds with hADSCs cultured in normal (NS), standard chondrogenic (CS) or modified chondrogenic + hBMP-6 medium (CS + hBMP-6). The chitosan scaffolds are a brownish colour, whereas living cell nuclei and matrix are a pinkish. Magnification set a 10x.

Additional file 2: Supplementary Figure 2. Immunohistochemical staining of collagen type X at day 7, 14 and 28 in chitosan scaffolds with hADSCs cultured in normal (NS), standard chondrogenic (CS) or modified chondrogenic + hBMP-6 medium (CS + hBMP-6). The chitosan scaffolds are a brownish colour, whereas living cell nuclei and matrix are a pinkish. Magnification set a 10x.

Additional file 3: Supplementary Figure 3. Relative gene expression quantity of (A) ACAN, (B) COL1A1, (C) COL2A1, (D) COL10A1, (E) COMP and (F) SOX9 between all-time points (day 7, 14 and 28) per 3D pellet or chitosan scaffolds culture medium group (N = normal medium; C = chondrogenic medium, P = 3D Pellet; S = chitosan scaffolds). (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). The baseline 0 represents untreated hADSCs in monolayer, which was the normalisation factor.

Abbreviations

3D: Three-Dimensional; ECM: Extracellular Matrix; MSC: Mesenchymal stem cells; hADSC: Human adipose-derived stem cells; h: Hour; min: Minutes; GAG: Glycosaminoglycan; DMEM: Dulbecco's modified eagle medium; SEM: Scanning electron microscope; qRT-PCR: Quantitative real-time polymerase chain reaction; hTGF- β_3 : Human transforming growth factor beta 3; hBMP-6: Human bone morphogenetic protein 6; WST-1: Water soluble tetrazolium - 1; NCHI: Chitosan in normal growth medium; NP: Pellet in normal growth medium; CP: Pellet in standard chondrogenic growth medium; ACAN: Aggrecan; COL1A1: Collagen type I; COL2A1: Collagen type II; COL10A1: Collagen type X; SOX9: SRY-box 9; COMP: Cartilage oligomeric matrix protein; NRQ: Normalized relative quantity; TBP: TATA sequence binding protein; SDHA: Succinate dehydrogenase complex flavoprotein subunit A; RPLP0: Ribosomal protein lateral stalk subunit P0; RPL13a: Ribosomal Protein L13a; PBS: Phosphate buffered saline; FCS: Fetal

calf/bovine serum; SD: Standard deviation; CS: Chitosan scaffold in standard chondrogenic growth medium; NS: Scaffold in normal growth medium

Acknowledgments

We would like to thank Ms. Bärbel Schmitt, our MTA, for her assistance in the cellular culturing techniques and Dr. Maryna Bondarava for having extracted the hADSCs. From Bayreuth we also would like to gratefully thank and acknowledge Mr. Florian Gaudig for the precise fabrication of the chitosan scaffolds.

Authors' contributions

Conceptualization, RMK; Methodology, RMK; Software, RMK and YC; Validation, RMK, DS, YC; Formal analysis, RMK and YH; Investigation, YH; Resources, VJ; Data curation, YH and RMK; Writing—original draft preparation, YH; Writing—review and editing, DS, YC, PEM, VJ, RMK; Visualization, YH and RMK; Supervision, PEM and RMK; Project administration, RMK; Funding acquisition, VJ". All authors consent and approved the final version of the manuscript.

Funding

This research was funded by Friedrich Baur Foundation under the Upper Franconian Project Program (project acronym/number "CaMuTE-Basic") and supported by the Chinese Scholarship Council/LMU program (#201608330225). The funding bodies were not involved in the design of the study, the collection of data, data analysis, in the interpretation of data and in writing the manuscript. Open access funding provided by Projekt DEAL.

Availability of data and materials

The necessary algorithmic codes of the program GeNorm are readily available at (https://www.researchgate.net/publication/343548360_GeNorm_v35_xl; <https://genorm.cmgg.be/>). All data, raw and processed, is readily available from the corresponding author on request.

Ethics approval and consent to participate

Human ADSCs were isolated, as previously described [31, 88], from subcutaneous adipose tissue that was acquired from the Biobank of the University Hospital of Munich Germany which operates in accordance to the European Union compliant ethical and legal framework of the Human Tissue and Cell Research Foundation (<http://www.htcr.org>). The research was approved by the Human Ethics Committee of the Faculty of Medicine at the University of Munich and the Bavarian State Medical Association (FB-Nr.: 7.1.1_VFD_FO_1). No stem cells were purchased commercially or otherwise. All cells utilized in the study were extracted by our laboratories in [88] extracted from the adipose tissue collected by the Biobank of the University Hospital of Munich Germany, who obtained written consent from participants in the donation of their adipose tissue.

Consent for publication

Not applicable.

Competing interests

The authors declare no conflict of interest.

Author details

¹Department of Orthopaedics, Physical Medicine and Rehabilitation, University Hospital of Munich, 81377 Munich, Germany. ²BioMed Center Innovation gGmbH, 95448 Bayreuth, Germany.

Received: 11 February 2020 Accepted: 20 August 2020

Published online: 27 August 2020

References

- Makris EA, Gomoll AH, Malizos KN, Hu JC, Athanasiou KA. Repair and tissue engineering techniques for articular cartilage. *Nat Rev Rheumatol*. 2015;11: 21–34. <https://doi.org/10.1038/nrrheum.2014.157>.
- Hunter, W. On the structure and diseases of articulating cartilage. *Phil Trans R Soc A* 1743, 42B, 514–521.
- Marijnissen AC, Lafeber FP. Re: E. B. Hunziker. Articular cartilage repair: basic science and clinical progress. A review of the current status and prospects. *Osteoarthritis and cartilage* 2002; 10:432-63. *Osteoarthr Cartil*. 2003;11:300–1 author reply 302-304.

4. Mandelbaum BR, Browne JE, Fu F, Micheli L, Mosely JB Jr, Erggelet C, Minas T, Peterson L. Articular cartilage lesions of the knee. *Am J Sports Med.* 1998; 26:853–61. <https://doi.org/10.1177/03635465980260062201>.
5. Johnstone B, Alini M, Cucchiari M, Dodge GR, Eglin D, Guilak F, Madry H, Mata A, Mauck RL, Semino CE, et al. Tissue engineering for articular cartilage repair—the state of the art. *Eur Cell Mater.* 2013;25:248–67.
6. Campbell CJ, Ishida H, Takahashi H, Kelly F. The transplantation of articular cartilage. An experimental study in dogs. *J Bone Joint Surg Am.* 1963;45:1579–92.
7. Karuppal R. Current concepts in the articular cartilage repair and regeneration. *J Orthop.* 2017;14:A1–3. <https://doi.org/10.1016/j.jor.2017.05.001>.
8. Correa D, Lietman SA. Articular cartilage repair: current needs, methods and research directions. *Semin Cell Dev Biol.* 2017;62:67–77. <https://doi.org/10.1016/j.semcdb.2016.07.013>.
9. Minas T. Autologous chondrocyte implantation for focal chondral defects of the knee. *Clin Orthop Relat Res.* 2001;(391 Suppl):S349–61. <https://doi.org/10.1097/00003086-200110001-00032>.
10. Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. *N Engl J Med.* 1994;331:889–95. <https://doi.org/10.1056/NEJM199410063311401>.
11. Gaut C, Sugaya K. Critical review on the physical and mechanical factors involved in tissue engineering of cartilage. *Regen Med.* 2015;10:665–79.
12. Darling EM, Athanasios KA. Rapid phenotypic changes in passaged articular chondrocyte subpopulations. *J Orthop Res.* 2005;23:425–32. <https://doi.org/10.1016/j.orthres.2004.08.008>.
13. Peterson L, Brittberg M, Kiviranta I, Akerlund EL, Lindahl A. Autologous chondrocyte transplantation. *Biomechanics and long-term durability.* *Am J Sports Med.* 2002;30:2–12. <https://doi.org/10.1177/03635465020300011601>.
14. Chen S, Fu P, Cong R, Wu H, Pei M. Strategies to minimize hypertrophy in cartilage engineering and regeneration. *Genes Dis.* 2015;2:76–95. <https://doi.org/10.1016/j.gendis.2014.12.003>.
15. Li YY, Cheng HW, Cheung KM, Chan D, Chan BP. Mesenchymal stem cell-collagen microspheres for articular cartilage repair: cell density and differentiation status. *Acta Biomater.* 2014;10:1919–29. <https://doi.org/10.1016/j.actbio.2014.01.002>.
16. Vinatier C, Bouffi C, Merceron C, Gordeladze J, Brondello JM, Jorgensen C, Weiss P, Guicheux J, Noel D. Cartilage tissue engineering: towards a biomaterial-assisted mesenchymal stem cell therapy. *Curr Stem Cell Res Ther.* 2009;4:318–29.
17. Wakitani S, Goto T, Pineda SJ, Young RG, Mansour JM, Caplan AI, Goldberg VM. Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. *J Bone Joint Surg Am.* 1994;76:579–92.
18. Tang C, Jin C, Du X, Yan C, Min BH, Xu Y, Wang L. An autologous bone marrow mesenchymal stem cell-derived extracellular matrix scaffold applied with bone marrow stimulation for cartilage repair. *Tissue Eng Part A.* 2014; 20:2455–62. <https://doi.org/10.1089/ten.TEA.2013.0464>.
19. English K, Mahon BP, Wood KJ. Mesenchymal stromal cells; role in tissue repair, drug discovery and immune modulation. *Curr Drug Deliv.* 2014;11:561–71.
20. Helder MN, Knippenberg M, Klein-Nulend J, Wuisman PI. Stem cells from adipose tissue allow challenging new concepts for regenerative medicine. *Tissue Eng.* 2007;13:1799–808. <https://doi.org/10.1089/ten.2006.0165>.
21. Elabd C, Chiellini C, Massoudi A, Cochet O, Zaragosi LE, Trojani C, Michiels JF, Weiss P, Carle G, Rochet N, et al. Human adipose tissue-derived multipotent stem cells differentiate in vitro and in vivo into osteocyte-like cells. *Biochem Biophys Res Commun.* 2007;361:342–8. <https://doi.org/10.1016/j.bbrc.2007.06.180>.
22. Tapp H, Hanley EN Jr, Patt JC, Gruber HE. Adipose-derived stem cells: characterization and current application in orthopaedic tissue repair. *Exp Biol Med (Maywood).* 2009;234:1–9. <https://doi.org/10.3181/0805/MR-170>.
23. Rodriguez AM, Elabd C, Amri EZ, Ailhaud G, Dani C. The human adipose tissue is a source of multipotent stem cells. *Biochimie.* 2005;87:125–8. <https://doi.org/10.1016/j.biochi.2004.11.007>.
24. Estes BT, Wu AW, Storms RW, Guilak F. Extended passaging, but not aldehyde dehydrogenase activity, increases the chondrogenic potential of human adipose-derived adult stem cells. *J Cell Physiol.* 2006;209:987–95. <https://doi.org/10.1002/jcp.20808>.
25. White EW, Weber JN, Roy DM, Owen EL, Chiroff RT, White RA. Replamineform porous biomaterials for hard tissue implant applications. *J Biomed Mater Res.* 1975;9:23–7. <https://doi.org/10.1002/jbm.820090406>.
26. Ripamonti U. The induction of bone in osteogenic composites of bone matrix and porous hydroxyapatite replicas: an experimental study on the baboon (*Papio ursinus*). *J Oral Maxillofac Surg.* 1991;49:817–30.
27. Nettles DL, Elder SH, Gilbert JA. Potential use of chitosan as a cell scaffold material for cartilage tissue engineering. *Tissue Eng.* 2002;8:1009–16. <https://doi.org/10.1089/107632702320934100>.
28. Di Martino A, Sittinger M, Risbud MV. Chitosan: a versatile biopolymer for orthopaedic tissue-engineering. *Biomaterials.* 2005;26:5983–90. <https://doi.org/10.1016/j.biomaterials.2005.03.016>.
29. Ye C, Hu P, Ma MX, Xiang Y, Liu RG, Shang XW. PHB/PHBHHx scaffolds and human adipose-derived stem cells for cartilage tissue engineering. *Biomaterials.* 2009;30:4401–6. <https://doi.org/10.1016/j.biomaterials.2009.05.001>.
30. Liu J, Zhao B, Zhang Y, Lin Y, Hu P, Ye C. PHBV and pre-differentiated human adipose-derived stem cells for cartilage tissue engineering. *J Biomed Mater Res A.* 2010;94:603–10. <https://doi.org/10.1002/jbm.a.32730>.
31. Huang Y, Seitz D, König F, Müller PE, Jansson V, Klar RM. Induction of articular chondrogenesis by chitosan/hyaluronic-acid-based biomimetic matrices using human adipose-derived stem cells. *Int J Mol.* 2019;20. <https://doi.org/10.3390/ijms20184487>.
32. Middleton JC, Tipton AJ. Synthetic biodegradable polymers as orthopedic devices. *Biomaterials.* 2000;21:2335–46.
33. Guilak F, Cohen DM, Estes BT, Gimble JM, Liedtke W, Chen CS. Control of stem cell fate by physical interactions with the extracellular matrix. *Cell Stem Cell.* 2009;5:17–26. <https://doi.org/10.1016/j.stem.2009.06.016>.
34. Cheng NC, Estes BT, Awad HA, Guilak F. Chondrogenic differentiation of adipose-derived adult stem cells by a porous scaffold derived from native articular cartilage extracellular matrix. *Tissue Eng Part A.* 2009;15:231–41. <https://doi.org/10.1089/ten.tea.2008.0253>.
35. Kazemnejad S, Khanmohammadi M, Mobini S, Taghizadeh-Jahed M, Khanjani S, Arasteh S, Golshahi H, Torkaman G, Ravanbod R, Heidari-Vala H, et al. Comparative repair capacity of knee osteochondral defects using regenerated silk fiber scaffolds and fibrin glue with/without autologous chondrocytes during 36 weeks in rabbit model. *Cell Tissue Res.* 2016;364: 559–72. <https://doi.org/10.1007/s00441-015-2355-9>.
36. Aguiar DJ, Knudson W, Knudson CB. Internalization of the hyaluronan receptor CD44 by chondrocytes. *Exp Cell Res.* 1999;252:292–302. <https://doi.org/10.1006/excr.1999.4641>.
37. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. *J Biol Chem.* 2008;283:17635–51. <https://doi.org/10.1074/jbc.M800109200>.
38. Harb N, Archer TK, Sato N. The rho-rock-mysin signaling axis determines cell-cell integrity of self-renewing pluripotent stem cells. *PLoS One.* 2008;3: e3001. <https://doi.org/10.1371/journal.pone.0003001>.
39. Culty M, Miyake K, Kincade PW, Sikorski E, Butcher EC, Underhill C. The hyaluronate receptor is a member of the CD44 (H-CAM) family of cell surface glycoproteins. *J Cell Biol.* 1990;111:2765–74.
40. Ripamonti U, Duneas N, Van den Heever B, Bosch C, Crooks J. Recombinant transforming growth factor-beta1 induces endochondral bone in the baboon and synergizes with recombinant osteogenic protein-1 (bone morphogenetic protein-7) to initiate rapid bone formation. *J Bone Miner Res.* 1997;10:1584–95.
41. Ripamonti U, Crooks J, Matsaba T, Tasker J. Induction of endochondral bone formation by recombinant human transforming growth factor-beta2 in the baboon (*Papio ursinus*). *Growth Factors.* 2000;17:269–85.
42. Ripamonti U, Ramoshebi LN, Teare J, Renton L, Ferretti C. The induction of endochondral bone formation by transforming growth factor-beta(3): experimental studies in the non-human primate *Papio ursinus*. *J Cell Mol Med.* 2008;12:1029–48. <https://doi.org/10.1111/j.1582-4934.2008.00126.x>.
43. Ude CC, Chen HC, Norhamdan MY, Azizi BM, Aminuddin BS, Ruszymah BH. The evaluation of cartilage differentiations using transforming growth factor beta3 alone and with combination of bone morphogenetic protein-6 on adult stem cells. *Cell Tissue Bank.* 2017;18:355–67. <https://doi.org/10.1007/s10561-017-9638-1>.
44. Vukicevic S, Grgurevic L. BMP-6 and mesenchymal stem cell differentiation. *Cytokine Growth Factor Rev.* 2009;20:441–8. <https://doi.org/10.1016/j.cytogfr.2009.10.020>.
45. Cook SD, Rueger DC. Osteogenic protein-1: biology and applications. *Clin Orthop Relat Res.* 1996;324:29–38.
46. Choi S, Cho T-J, Kwon S-K, Lee G, Cho J. Chondrogenesis of periodontal ligament stem cells by transforming growth factor- β 3 and bone

- morphogenetic protein-6 in a normal healthy impacted third molar. *Int J Oral Sci.* 2013;5:7–13. <https://doi.org/10.1038/ijos.2013.19>.
47. Taghavi M, Parham A, Raji A. The combination of TGF- β_3 and BMP-6 synergistically promotes chondrogenic differentiation of equine bone-marrow derived mesenchymal stem cells. *Int J Peptide Res Therap.* 2019;22:1–10. <https://doi.org/10.1007/s10989-019-09880-w>.
 48. Ye F, Xu H, Yin H, Zhao X, Li D, Zhu Q, Wang Y. The role of BMP-6 in the proliferation and differentiation of chicken cartilage cells. *PLoS One.* 2019;7:e0204384. <https://doi.org/10.1371/journal.pone.0204384>.
 49. Levengood SL, Zhang M. Chitosan-based scaffolds for bone tissue engineering. *J Mater Chem B.* 2014;2(21):3161–84.
 50. Huang Y, Onyeri S, Siewe M, Moshfeghian A, Madihally SV. In vitro characterization of chitosan-gelatin scaffolds for tissue engineering. *Biomaterials.* 2005;26(36):7616–27.
 51. Park H, Choi B, Hu J, Lee M. Injectable chitosan hyaluronic acid hydrogels for cartilage tissue engineering. *Acta Biomater.* 2013;9:4779–86. <https://doi.org/10.1016/j.actbio.2012.08.033>.
 52. Florczyk SJ, Wang K, Jana S, Wood DL, Sytsma SK, Sham J, Kievit FM, Zhang M. Porous chitosan-hyaluronic acid scaffolds as a mimic of glioblastoma microenvironment ECM. *Biomaterials.* 2013;34:10143–50. <https://doi.org/10.1016/j.biomaterials.2013.09.034>.
 53. Tan H, Chu CR, Payne KA, Marra KG. Injectable in situ forming biodegradable chitosan-hyaluronic acid based hydrogels for cartilage tissue engineering. *Biomaterials.* 2009;30:2499–506. <https://doi.org/10.1016/j.biomaterials.2008.12.080>.
 54. Mohan N, Mohanan PV, Sabareeswaran A, Nair P. Chitosan-hyaluronic acid hydrogel for cartilage repair. *Int J Biol Macromol.* 2017;104:1936–45. <https://doi.org/10.1016/j.ijbiomac.2017.03.142>.
 55. Long F, Linsenmayer TF. Tissue-specific regulation of the type X collagen gene. Analyses by in vivo footprinting and transfection with a proximal promoter region. *J Biol Chem.* 1995;270:31310–4.
 56. Benya PD, Padilla SR, Nimni ME. Independent regulation of collagen types by chondrocytes during the loss of differentiated function in culture. *Cell.* 1978;15:1313–21.
 57. Zheng B, Cao B, Li G, Huard J. Mouse adipose-derived stem cells undergo multilineage differentiation in vitro but primarily osteogenic and chondrogenic differentiation in vivo. *Tissue Eng.* 2006;12:1891–901. <https://doi.org/10.1089/ten.2006.12.1891>.
 58. Blanpain C, Fuchs E. Stem cell plasticity. Plasticity of epithelial stem cells in tissue regeneration. *Science.* 2014;344:1242281. <https://doi.org/10.1126/science.1242281>.
 59. Chandry T, Sharma CP. Chitosan—as a biomaterial. *Biomater Artif Cells Artif Organs.* 1990;18:1–24.
 60. Shim IK, Suh WH, Lee SY, Lee SH, Heo SJ, Lee MC, Lee SJ. Chitosan nano-/microfibrous double-layered membrane with rolled-up three-dimensional structures for chondrocyte cultivation. *J Biomed Mater Res A.* 2009;90:595–602. <https://doi.org/10.1002/jbm.a.32109>.
 61. Razavi S, Zarkesh-Esfahani H, Morshed M, Vaezifar S, Karbasi S, Golozar MA. Nanobiocomposite of poly(lactide-co-glycolide)/chitosan electrospun scaffold can promote proliferation and transdifferentiation of Schwann-like cells from human adipose-derived stem cells. *J Biomed Mater Res A.* 2015;103:2628–34. <https://doi.org/10.1002/jbm.a.35398>.
 62. Ghorbani FM, Kaffashi B, Shokrollahi P, Seyedjafari E, Ardeshiryajami A. PCL/chitosan/Zn-doped nHA electrospun nanocomposite scaffold promotes adipose derived stem cells adhesion and proliferation. *Carbohydr Polym.* 2015;118:133–42. <https://doi.org/10.1016/j.carbpol.2014.10.071>.
 63. Fang J, Zhang Y, Yan S, Liu Z, He S, Cui L, Yin J. Poly(L-glutamic acid)/chitosan polyelectrolyte complex porous microspheres as cell microcarriers for cartilage regeneration. *Acta Biomater.* 2014;10:276–88. <https://doi.org/10.1016/j.actbio.2013.09.002>.
 64. Klar RM. The induction of bone formation: the translation enigma. *Front Bioeng Biotechnol.* 2018;6:74. <https://doi.org/10.3389/fbioe.2018.00074>.
 65. Yu Y, Wei N, Stanford C, Schmidt T, Hong L. In vitro effects of RU486 on proliferation and differentiation capabilities of human bone marrow mesenchymal stromal cells. *Steroids.* 2012;77:132–7. <https://doi.org/10.1016/j.stero.2011.10.017>.
 66. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells. *Exp Cell Res.* 1998;238:265–72. <https://doi.org/10.1006/excr.1997.3858>.
 67. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UJ, Liotta LA, Falanga V, Kheir JH. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. *Proc Natl Acad Sci U S A.* 1986;83:4167–71.
 68. Ripamonti U, Parak R, Klar RM, Dickens C, Dix-Peek T, Duarte R. The synergistic induction of bone formation by the osteogenic proteins of the TGF- β supergene family. *Biomaterials.* 2016;104:279–96. <https://doi.org/10.1016/j.biomaterials.2016.07.018>.
 69. Klar RM, Duarte R, Dix-Peek T, Ripamonti U. The induction of bone formation by the recombinant human transforming growth factor- β_3 . *Biomaterials.* 2014;35:2773–88. <https://doi.org/10.1016/j.biomaterials.2013.12.062>.
 70. Boumediene K, Vivien D, Macro M, Bogdanowicz P, Lebrun E, Pujol JP. Modulation of rabbit articular chondrocyte (RAC) proliferation by TGF-beta isoforms. *Cell Prolif.* 1995;28(4):221–34.
 71. Wang R, Xu B, Xu H. TGF- β_1 promoted chondrocyte proliferation by regulating Sp1 through MSC-exosomes derived miR-135b. *Cell Cycle.* 2018;11:17(24).
 72. Grimsrud CD, Romano PR, D'souza M, Puzas JE, Reynolds PR, Rosier RN, O'keefe RJ. BMP-6 is an Autocrine stimulator of chondrocyte differentiation. *J Bone Miner Res.* 1999;14:475–82.
 73. Yamane S, Iwasaki N, Majima T, Funakoshi T, Masuko T, Harada K, Minami A, Monde K, Nishimura S. Feasibility of chitosan-based hyaluronic acid hybrid biomaterial for a novel scaffold in cartilage tissue engineering. *Biomaterials.* 2005;26:611–9. <https://doi.org/10.1016/j.biomaterials.2004.03.013>.
 74. Kim IL, Mauck RL, Burdick JA. Hydrogel design for cartilage tissue engineering: a case study with hyaluronic acid. *Biomaterials.* 2011;32:8771–82. <https://doi.org/10.1016/j.biomaterials.2011.08.073>.
 75. Correia CR, Moreira-Teixeira LS, Moroni L, Reis RL, van Blitterswijk CA, Karperien M, Mano JF. Chitosan scaffolds containing hyaluronic acid for cartilage tissue engineering. *Tissue Eng Part C Methods.* 2011;17:717–30. <https://doi.org/10.1089/ten.tec.2010.0467>.
 76. Wu SC, Chen CH, Wang JY, Lin YS, Chang JK, Ho ML. Hyaluronan size alters chondrogenesis of adipose-derived stem cells via the CD44/ERK/SOX-9 pathway. *Acta Biomater.* 2018;66:224–37. <https://doi.org/10.1016/j.actbio.2017.11.025>.
 77. Bono P, Rubin K, Higgins JM, Hynes RO. Layilin, a novel integral membrane protein, is a hyaluronan receptor. *Mol Biol Cell.* 2001;12:891–900. <https://doi.org/10.1091/mbc.12.4.891>.
 78. Tang S, Spector M. Incorporation of hyaluronic acid into collagen scaffolds for the control of chondrocyte-mediated contraction and chondrogenesis. *Biomed Mater.* 2007;2:S135–41. <https://doi.org/10.1088/1748-6041/2/3/S10>.
 79. Chung C, Burdick JA. Influence of three-dimensional hyaluronic acid microenvironments on mesenchymal stem cell chondrogenesis. *Tissue Eng Part A.* 2009;15:243–54. <https://doi.org/10.1089/ten.tea.2008.0067>.
 80. Responde DJ, Natoli RM, Athanasiou KA. Identification of potential biophysical and molecular signalling mechanisms underlying hyaluronic acid enhancement of cartilage formation. *J R Soc Interface.* 2012;9:3564–73. <https://doi.org/10.1098/rsif.2012.0399>.
 81. Huang GS, Dai LG, Yen BL, Hsu SH. Spheroid formation of mesenchymal stem cells on chitosan and chitosan-hyaluronan membranes. *Biomaterials.* 2011;32:6929–45. <https://doi.org/10.1016/j.biomaterials.2011.05.092>.
 82. Matsiko A, Levingstone TJ, O'Brien FJ, Gleeson JP. Addition of hyaluronic acid improves cellular infiltration and promotes early-stage chondrogenesis in a collagen-based scaffold for cartilage tissue engineering. *J Mech Behav Biomed Mater.* 2012;11:41–52. <https://doi.org/10.1016/j.jmbbm.2011.11.012>.
 83. Mahmoudifar N, Doran PM. Chondrogenic differentiation of human adipose-derived stem cells in polyglycolic acid mesh scaffolds under dynamic culture conditions. *Biomaterials.* 2010;31:3858–67. <https://doi.org/10.1016/j.biomaterials.2010.01.090>.
 84. Hecht JT, Hayes E, Haynes R, Cole WG. COMP mutations, chondrocyte function and cartilage matrix. *Matrix Biol.* 2005;23:525–33. <https://doi.org/10.1016/j.matbio.2004.09.006>.
 85. Di Cesare PE, Chen FS, Moergelin M, Carlson CS, Leslie MP, Perris R, Fang C. Matrix-matrix interaction of cartilage oligomeric matrix protein and fibronectin. *Matrix Biol.* 2002;21:461–70.
 86. Chen FH, Herndon ME, Patel N, Hecht JT, Tuan RS, Lawler J. Interaction of cartilage oligomeric matrix protein/thrombospondin 5 with aggrecan. *J Biol Chem.* 2007;282:24591–8. <https://doi.org/10.1074/jbc.M611390200>.
 87. Hamid AA, Idrus RB, Saim AB, Sathappan S, Chua KH. Characterization of human adipose-derived stem cells and expression of chondrogenic genes during induction of cartilage differentiation. *Clinics (Sao Paulo).* 2012;67:99–106.

88. Denton N, Pinnick KD, Karpe F. Cartilage oligomeric matrix protein is differentially expressed in human subcutaneous adipose tissue and regulates adipogenesis. *Mol Metab.* 2018;16:172–9.
89. Wehrli BM, Huang W, De Crombrughe B, Ayala AG, Czerniak B. Sox9, a master regulator of chondrogenesis, distinguishes mesenchymal chondrosarcoma from other small blue round cell tumors. *Hum Pathol.* 2003;34:263–9. <https://doi.org/10.1053/hupa.2003.41>.
90. Dehne T, Schenk R, Perka C, Morawietz L, Pruss A, Sittlinger M, Kaps C, Ringe J. Gene expression profiling of primary human articular chondrocytes in high-density micromasses reveals patterns of recovery, maintenance, re- and dedifferentiation. *Gene.* 2010;462:8–17. <https://doi.org/10.1016/j.gene.2010.04.006>.
91. Unguryte A, Bernotiene E, Bagdonas E, Garberyste S, Porvaneckas N, Jorgensen C. Human articular chondrocytes with higher aldehyde dehydrogenase activity have stronger expression of COL2A1 and SOX9. *Osteoarthr Cartil.* 2016;24:873–82. <https://doi.org/10.1016/j.joca.2015.11.019>.
92. Goh BS, Che Omar SN, Ubaidah MA, Saim L, Sulaiman S, Chua KH. Chondrogenesis of human adipose derived stem cells for future microtia repair using co-culture technique. *Acta Otolaryngol.* 2017;4:432–41. <https://doi.org/10.1080/00016489.2016.1257151>.
93. Kawakami Y, Rodriguez-Leon J, Izpisua Belmonte JC. The role of TGFbetas and Sox9 during limb chondrogenesis. *Curr Opin Cell Biol.* 2006;18:723–9. <https://doi.org/10.1016/j.ceb.2006.10.007>.
94. Roman-Blas JA, Stokes DG, Jimenez SA. Modulation of TGF-beta signaling by proinflammatory cytokines in articular chondrocytes. *Osteoarthr Cartil.* 2007; 15:1367–77. <https://doi.org/10.1016/j.joca.2007.04.011>.
95. He T, Huang Y, Chak JC, Klar RM. Recommendations for improving accuracy of gene expression data in bone and cartilage tissue engineering. *Sci Rep.* 2018;8:14874. <https://doi.org/10.1038/s41598-018-33242-z>.
96. Kuo AC, Rodrigo JJ, Reddi AH, Curtiss S, Grotkopp E, Chiu M. Microfracture and bone morphogenetic protein 7 (BMP-7) synergistically stimulate articular cartilage repair. *Osteoarthr Cartil.* 2006;14:1126–35. <https://doi.org/10.1016/j.joca.2006.04.004>.
97. Weber M, Steinert A, Jork A, Dimmler A, Thurmer F, Schutze N, Hendrich C, Zimmerman U. Formation of cartilage matrix proteins by BMP-transfected murine mesenchymal stem cells encapsulated in a novel class of alginates. *Biomaterials.* 2002;23:2003–13.
98. Fischer L, Boland G, Tuan RS. Wnt signaling during BMP-2 stimulation of mesenchymal chondrogenesis. *J Cell Biochem.* 2002;84:816–31.
99. Gelse K, Muhle C, Franke O, Park J, Jehle M, Durst K, Goken M, Hennig F, von der Mark K, Schneider H. Cell-based resurfacing of large cartilage defects: long-term evaluation of grafts from autologous transgene-activated periosteal cells in a porcine model of osteoarthritis. *Arthritis Rheum.* 2008; 58:475–88. <https://doi.org/10.1002/art.23124>.
100. Klar RM. Bone induction: regeneration through chaos. *Front Physiol.* 2011;2: 21. <https://doi.org/10.3389/fphys.2011.00021>.
101. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin Chem.* 2009;55:611–22. <https://doi.org/10.1373/clinchem.2008.112797>.
102. Bondarava M, Cattaneo C, Ren B, Thasler WE, Jansson V, Muller PE, Betz OB. Osseous differentiation of human fat tissue grafts: from tissue engineering to tissue differentiation. *Sci Rep.* 2017;7:39712. <https://doi.org/10.1038/srep39712>.
103. Estes BT, Guilak F. Three-dimensional culture systems to induce chondrogenesis of adipose-derived stem cells. *Methods Mol Biol.* 2011;702: 201–17. https://doi.org/10.1007/978-1-61737-960-4_15.
104. Chomczynski P, Mackey K. Short technical reports. Modification of the TRI reagent procedure for isolation of RNA from polysaccharide- and proteoglycan-rich sources. *Biotechniques.* 1995;19:942–5.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

